City Therapeutics sets IPO terms at $17-$19 per share, targeting up to $956M valuation

City Therapeutics, a developer of RNA-based rare disease drugs, is seeking to raise up to $184.7 million in a US IPO by offering 9.7 million shares at $17 to $19 each, targeting a valuation of up to $956 million. Goldman Sachs and Jefferies are among the underwriters.

Detected & updated continuously · Source: Nebula